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CC BY-NC-ND license (http://creativeBackground/Purpose: Although clopidogrel does not cause gastric mucosal injury, it does not
prevent peptic ulcer recurrence in high-risk patients. We explored whether clopidogrel delays
gastric ulcer healing via inhibiting angiogenesis and to elucidate the possible mechanisms.
Methods: Gastric ulcers were induced in Sprague Dawley rats, and ulcer healing and angiogen-
esis of ulcer margin were compared between clopidogrel-treated rats and controls. The ex-
pressions of the proangiogenic growth factors and their receptors including basic fibroblast
growth factor (bFGF), bFGF receptor (FGFR), vascular endothelial growth factor (VEGF),
VEGFR1, VEGFR2, platelet-derived growth factor (PDGF)A, PDGFB, PDGFR A, PDGFR B, and
phosphorylated form of mitogenic activated protein kinase pathways over the ulcer margin
were compared via western blot and reverse transcription polymerase chain reaction.
In vitro, human umbilical vein endothelial cells (HUVECs) were used to elucidate how clopido-
grel inhibited growth factors-stimulated HUVEC proliferation.
Results: The ulcer sizes were significantly larger and the angiogenesis of ulcer margin was
significantly diminished in the clopidogrel (2 and 10 mg/kg/d) treated groups. Ulcer induction
markedly increased the expression of phosphorylated form of extracellular signal-regulated ki-
nase (pERK), FGFR2, VEGF, VEGFR2, and PDGFRA when compared with those of normal mucosa.
Clopidogrel treatment significantly decreased pERK, FGFR2, VEGF, VEGFR2, and PDGFRAhave no conflicts of interest relevant to this article.
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an Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
Clopidogrel inhibits ulcer healing 765expression at the ulcer margin when compared with those of the respective control group.
In vitro, clopidogrel (106M) inhibited VEGF-stimulated (20 ng/mL) HUVEC proliferation, at
least, via downregulation of VEGFR2 and pERK.
Conclusion: Clopidogrel inhibits the angiogenesis of gastric ulcer healing at least partially by
the inhibition of the VEGFeVEGFR2eERK signal transduction pathway.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Clopidogrel is an alternative antiplatelet agent that inhibits
adenosine diphosphate (ADP)-induced platelet aggrega-
tion.1,2 Clopidogrel does not inhibit the function of cyclo-
oxygenases and does not induce endoscopically evident
gastric mucosal injury in volunteers.3 However, clopidogrel
is not safe enough for gastroduodenal mucosa in patients
with high risk for peptic ulcer bleeding.4,5 In fact, ulcer
formation is a dynamic imbalance between mucosal
aggressive factors and defensive/repairing factors. When
the function of defense and repairing factors is less than
that of aggressive factors, mucosal injury worsens, and
then finally ulcer formation develops.6 Animal studies have
shown that another platelet ADP-receptor antago-
nistdticlopidinedimpairs the healing of rat gastric ulcer
by inhibiting the release of platelet derived growth factor
(PDGF).7,8
The healing of gastric ulcer requires the reconstruction
of epithelial structures and the underlying connective tis-
sue, involving cell proliferation and angiogenesis.6,9 Several
growth factors have been implicated in the ulcer healing
process.10 The expression of these growth factors and their
receptors are strongly increased over the ulcer margin.10e12
In these growth factors, basic fibroblast growth factor
(bFGF), vascular endothelial growth factor (VEGF), PDGF,
and their receptors are mainly involved in the
angiogenesis.10,13,14
In this study, we demonstrated that clopidogrel delayed
rat gastric ulcer healing via inhibiting angiogenesis. In this
regard, we compared the ulcer size, and angiogenesis of
ulcer margin between clopidogrel-treated groups and con-
trols. The expressions of proangiogenic growth factors and
their receptors, and signal transduction pathways for
angiogenesis over the ulcer margin were also measured and
compared between clopidogrel-treated groups and con-
trols. In vitro, we used human umbilical vein endothelial
cells (HUVECs) to demonstrate that clopidogrel inhibited
VEGF-stimulated HUVEC proliferation.
Methods
Animals and chemicals
Male Sprague Dawley rats (200e220 g) were reared in a
standard laboratory environment.9 The Committee on the
Use of Live Animals in Taipei Veterans General Hospital
approved the use of animals in this study (No: 97e137). The
procedures followed were in accordance with institutionalguidelines. Chemicals and drugs were purchased from
Sigma-Aldrich (Sigma-Aldrich Biotechnology, St. Louis, MO,
USA) unless otherwise specified. Clopidogrel was suspended
in 1% methylcellulose vehicle for intragastric
administration.
Induction of gastric ulcer
Gastric kissing ulcers were induced by luminal application
of acetic acid to rats as previously described.9 The anterior
and posterior walls of the stomach were clamped together
with a pair of forceps with a round ring (internal diameter
10 mm) situated between the two arms of the forceps. A
70% acetic acid solution of 0.15 mL was injected into the
clamped portion via a 21-gauge needle. After 45 seconds,
the acid solution was removed and the abdomen was
closed.
Drug treatment and measurement of gastric ulcer
One day after ulcer induction, the rats were given intra-
gastric clopidogrel of 2 or 10 mg/kg once daily for 5 or 10
days, respectively, to observe the effect on ulcer healing.
The control rats were given 1% methylcellulose solution.
The dose of clopidogrel (2 and 10 mg/kg/d) did not cause
gastric mucosal injury in a previous study.15 After treat-
ment, the rats were sacrificed at Day 6 and 11, after ulcer
induction. The size (mm2) of ulcers on both the anterior and
posterior walls was measured. In order to check the pa-
rameters of the healing process, another group of rats
(intragastrically at doses of 2 or 10 mg/kg also) were
sacrificed at Days 4 and 9, respectively, after ulcer induc-
tion. Gastric tissues were excised for immunohistological
analysis. Gastric mucosa and submucosa over the ulcer
margins were also collected and frozen in liquid nitrogen
and stored at 70C until determinations for different pa-
rameters took place. The “normal group” means the group
of rats without ulcer induction and their gastric mucosa and
submucosa were intact.
Determination of angiogenesis at ulcer margin and
base
The microvessels at the ulcer margin and base in the
granulation tissue of the submucosa were identified by
immunonhistochemical staining with von Willebrand factor
(vWF) antibody (Santa Cruz Biotechnology Inc, Santa Cruz,
CA, USA).9 The microvessels stained with the antibody were
quantified at the two sides of the ulcer margin and at the
Table 1 Effect of clopidogrel on gastric ulcer healing.
Days after ulcer induction Ulcer size (mm2)
Day 6 Day 11
Control group 28  5 11  3
Clopidogrel 2 mg/kg/d 33  4* 14  3*
Clopidogrel 10 mg/kg/d 35  5* 18  3*
Values are mean  standard deviation of six to eight rats per
group.
*Indicates p < 0.05 when compared with the respective control
group.
Table 2 Effect of clopidogrel on angiogenesis of ulcer
margin and ulcer base.
Numbers of microvessels/mm2
Ulcer margin Ulcer base
Four days after ulcer induction
Control group 25.6  4.1* 17.1  3.6*
Clopidogrel 2 mg/kg/day 19.1  2.9 12.7  2.4
Clopidogrel 10 mg/kg/day 15.1  1.8** 11.2  1.1**
Nine days after ulcer induction
Control group 17.3  3.5* 12.3  2.9*
Clopidogrel 2 mg/kg/d 12.6  3.3 8.1  2.6
Clopidogrel 10 mg/kg/d 10.5  3.4** 7.8  2.4**
Normal group 7.1  1.1
Values are mean  standard deviation of six to eight rats per
group. Normal group means the group of rats without ulcer in-
duction.
*Indicates p < 0.05 when compared with the normal group.
**Indicates p < 0.05 when compared with the respective control
group.
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(200). The number of blood vessels at the ulcer margin
was expressed by taking the average of both sides of the
ulcer margin.9
Western blot for the expression of growth factors,
their receptors, and transduction pathways
Gastric tissues were homogenized and centrifuged for su-
pernatants. After concentration measuring using a protein
assay kit (BCA Protein Assay Kit, Pierce, Rockford, IL, USA),
proteins were separated using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to
Immobilon-P polyvinlidene fluoride (PVDF) transfer mem-
branes (Millipore, Billerica, MA, USA). These membranes
were then probed with antibodies against vWF, bFGF, FGF
receptor 1 (FGFR1), FGFR2, VEGF, VEGFR1, VEGFR2,
PDGFA, PDGFRA, PDGFB, PDGFRB, extracellular signal-
regulated kinase (ERK), P38 mitogen activated protein ki-
nase (MAPK), phosphatidylinositol 3-kinase (PI3K) and their
phosphorylated forms (pERK, pP38, and pPI3K), and b-actin
(Santa Cruz Biotechnology Inc) overnight at 4C and incu-
bated for 1 hour with secondary antibodies conjugated with
horseradish peroxidase. The membrane was developed
using the SuperSignal West Femto Trial Kit (Pierce) and
exposed to an X-ray film. Quantitation was performed using
a densitometer.16
Total RNA isolation and messenger RNA expression
of growth factors and their receptors
The total RNA was extracted from rat gastric mucosa using
the Total RNA Mini Kit (Geneaid, Taipei, Taiwan). The
quality of isolated RNA was verified and quantified by
NanoDrop 2000 (Thermo, Wilmington, DE, USA) measuring
its absorbance at 260- and 280-nm wavelengths. Single-
stranded complementary DNA (cDNA) was synthesized using
the SuperScript II reverse transcriptase (Invitrogen, Grand
Island, NY, USA) and oligo(dT) primer. Reverse transcrip-
tase- polymerase chain reaction (RT-PCR) primer sequences
were designed according to the published cDNA sequence
for rats from the National Center for Biotechnology Infor-
mation (NCBI) GenBank and Primer 3 program.16
The sequences of forward and reverse primers are
described in Table S1. The PCR was performed and each
PCR product was electrophoresed on 2% agarose gel stained
with ethidium bromide, and visualized under ultraviolet
light. PCR quantization was performed using the Image-J
system (NCBI published program).16
Culture of HUVECs
HUVECs were grown in M199 medium supplemented with
10% (v/v) fetal bovine serum (FBS), gentamicin sulfate
(50 mg/mL), 25 U/mL heparin, and 30 mg/mL endothelial
cell growth supplement (ECGS). The cells were cultivated
at 37C in a humidified atmosphere of 95% air and 5% carbon
dioxide (CO2). On the day before the experiment, the me-
dium was changed to 1% FBS for starvation and cell cycle
synchronization for 18 hours.Cell proliferation assay
Cell proliferation was measured using 3-(4,5-dimethyl-
thiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) reduc-
tion method.15 After synchronization for 18 hours and
treatment with different growth factors (10, 20, and 50 ng/
mL bFGF, VEGF, PDGFA, and PDGFB, respectively) and/or
clopidogrel (106M) for 24 hours, cells were incubated with
2.5% MTT solution (5 mg/mL) for another 3 hours at 37C.
Thereafter, medium was aspirated, 0.04 N HCl-isopropanol
was added and mixed thoroughly for 10 minutes. Color
change and optical densities were determined by the MRX
microplate reader (Dynex Technologies Inc., Chantilly, VA,
USA) at 570 nm.
Expression of growth factors, their receptors, and
transduction pathways in HUVECs
After synchronization, the HUVEC cells were treated with
different regimens and then were collected for Western
blot and real-time PCR analysis. To quantify the gene ex-
pressions of VEGFR1 and VEGFR2, quantitative real-time
PCR was performed using a LightCycler480 (Roche Applied
Science, Indianapolis, IN, USA) and on the LightCycler 480
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according to the manufacturer’s instructions.17 The signals
from each sample were normalized to values obtained for
housekeeping gene glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), which was run simultaneously with the
experimental samples. A comparative threshold cycle (Ct)
method (OOCt) was used to calculate the relative gene
expressions (fold change) between test and reference
samples. All the measurements were done in duplicate for
each sample. The sequences of forward and reverse
primers are: VEGFR1 50-AGGCAAGCGCAGGTTCAC-30 and 50-
AAGGCTTCGTGTCAAACTCTAGATG-30, respectively, with a
product of 130 base pairs (bp); VEGFR2 50-CAAAGGGTG-
GAGGTGACTGAGT-30 and 50-GTTTCCCGGTAGAAGCACTTGT-
30, respectively, with a product of 110 bp; GAPDH 50-
GGGTGTGAACCATGAGAAGT-30, and 50-ACTGTGGTCAT-
GAGTCCTTC-30, respectively, with a product of 135 bp.Statistical analysis
Results were expressed as mean  standard deviation.
There were six to eight samples in each group. DifferencesFigure 1 Effects of clopidogrel on protein expressions at Day 4 aft
to eight rats per group. * Indicates p < 0.05 when compared withbetween the means were analyzed with the Student t test
when appropriate with Bonferroni correction to adjust for
multiple comparisons in each experiment or one-way
analysis of variance. A value of p < 0.05 was considered
to be statistically significant.
Results
Effect of clopidogrel on gastric ulcer healing and
angiogenesis of ulcer healing
The average ulcer sizes on days 6 and 11 were larger in the
clopidogrel-treated groups (p < 0.05, Table 1), so delayed
gastric ulcer healing on days 6 and 11 after ulcer induction
was noted in the clopidogrel-treated groups compared with
the control group. The number of blood vessels at the ulcer
margin and base was markedly increased 4 and 9 days after
ulcer induction (p < 0.05). Administration of clopidogrel
significantly decreased numbers of microvessels at ulcer
base and ulcer margin in Day 4 and Day 9 after ulcer in-
duction in a dose-related manner when compared with
those of the respective control group (Table 2).er ulcer induction. Values are mean  standard deviation of six
each other.
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regarding angiogenesis of gastric ulcer healing
Ulcer induction markedly increased the protein expression of
vWF, FGFR2, VEGF, VEGFR2, PDGFRA, and pERK at Day 4 and
Day 9 after ulcer induction at the ulcer margin when
comparedwith thoseof thenormalmucosa. (p< 0.05; Figures
1 and 2). Clopidogrel treatment significantly decreased ulcer-
induced expression of vWF, FGFR2, VEGF, VEGFR2, PDGFRA,
and pERK at both Day 4 and Day 9 at the ulcer margin when
compared with the respective control group (p < 0.05;
Figures 1 and 2). However, the protein expression of bFGF,
FGFR1, VEGFR1, PDGFA, PDGFB, PDGFRB, ERK, PI3K, pPI3K,
P38, and pP38 at the gastric ulcermarginwas not significantly
different among the normal group, control group, and the
clopidogrel-treated groups (Figures 1 and 2).
Effects of clopidogrel on mRNA expressions of
growth factors and receptors of gastric ulcer
healing
Ulcer induction markedly increased the mRNA expression of
FGFR2, VEGF, VEGFR2, and PDGFRA at Day 4 and Day 9 after
ulcer induction at the ulcermarginwhen comparedwith thoseFigure 2 Effects of clopidogrel on protein expressions at Day 9 af
to eight rats per group. * Indicates p < 0.05 when compared withof the normal mucosa (p < 0.05; Figure 3). Clopidogrel
treatment significantly inhibited ulcer-induced mRNA
expression of FGFR2, VEGF, VEGFR2, and PDGFRA at Day 4 and
Day 9after ulcer inductionat theulcermarginwhencompared
with the respective control group (p < 0.05; Figure 3).
Effects of clopidogrel on growth factor-stimulated
HUVEC proliferation
There was no significant difference on HUVEC proliferation
(MTT method) when treated with different concentrations
of bFGF (10 ng/mL, 20 ng/mL, and 50 ng/mL), or VEGF
(10 ng/mL, 20 ng/mL, and 50 ng/mL), or PDGFA (10 ng/mL,
20 ng/mL, and 50 ng/mL), or PDGFB (10 ng/mL, 20 ng/mL,
and 50 ng/mL for 24 hours respectively (data not shown).
Samples of 20 ng/mL of bFGF, VEGF, PDGFA, PDGFB were
selected for further studies. After synchronization, VEGF
treatment (20 ng/mL) for 24 hours significantly increased
HUVEC proliferation when compared with the controls
(p < 0.05), whereas bFGF, PDGFA, PDGFB treatment (20 ng/
mL) for 24 hours did not significantly increase HUVEC pro-
liferation when compared with the controls (figure not
shown). Although clopidogrel treatment (106M) alone for
24 hours did not significantly decrease HUVEC proliferationter ulcer induction. Values are mean  standard deviation of six
each other.
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significantly diminished VEGF (20 ng/mL)-stimulated HUVEC
proliferation (p < 0.05; figure not shown).
Effects of clopidogrel on VEGF-stimulated
expression of pERK and VEGF receptors
After synchronization, VEGF treatment (20 ng/mL) for 10
minutes significantly increased protein expression of pERK,Figure 3 Effects of clopidogrel on messenger RNA expressions
mean  standard deviation of six to eight rats per group. * IndicatVEGFR1, VEGFR2 (p < 0.05; Figure 4), but not ERK, PI3K,
pPI3K, P38, or pP38 when compared with the controls (data
not shown). However, pretreatment with 106M clopidogrel
for 3 hours, significantly inhibited VEGF-stimulated protein
expression of pERK and VEGFR2 when compared with that
of VEGF group. Clopidogrel alone (106M) for 3 hours also
significantly inhibited the protein expression of pERK and
VEGFR2 when compared with the control (p < 0.05;
Figure 4).at (A) Day 4 and (B) Day 9 after ulcer induction. Values are
es p < 0.05 when compared with each other.
770 J.-C. Luo et al.Effects of clopidogrel on VEGF-stimulated mRNA
expression of VEGF receptors
After synchronization, VEGF treatment (20 ng/mL) for 10
minutes significantly increased mRNA expression of
VEGFR1, VEGFR2 when compared with the controls
(p < 0.05; Figure 5). The increase was more conspicuous on
VEGFR2 expression than VEGFR1 expression. However,
pretreatment with 106M clopidogrel for 3 hours signifi-
cantly inhibited VEGF-stimulated mRNA expression of
VEGFR1 and VEGFR2 when compared with that of the VEGF
group. The inhibition was more conspicuous on VEGFR2
expression than VEGFR1 expression. Clopidogrel alone
(106M) for 3 hours also significantly inhibited the mRNA
expression of VEGFR1 and VEGFR2 when compared with the
control (p < 0.05; Figure 5).
Discussion
In the current study, we demonstrated that clopidogrel
inhibited the angiogenesis of gastric ulcer healing in rats
and this was associated with diminished expression ofFigure 4 Effects of vascular endothelial growth factor
(VEGF) with or without clopidogrel on the protein expression of
VEGF receptor and phosphorylated forms extracellular signal-
regulated kinase (pERK). Values are mean  standard devia-
tion. nZ 6 in each group. * Indicates p < 0.05 when compared
with each other.FGFR2, VEGF, VEGFR2, PDGFRA, and pERK over the ulcer
margin. In vitro, we showed that clopidogrel inhibited
VEGF-stimulated HUVEC proliferation, at least, via down-
regulation of VEGFR2 and pERK. This study, for the first
time, demonstrated that clopidogrel inhibited angiogenesis
and delayed ulcer healing at least by the inhibition of the
VEGF-VEGFR2-ERK signal transduction pathway.
VEGF is secreted as dimeric glycoproteins and recognizes
specific receptors with intrinsic tyrosine kinase activity,
VEGFR1 and VEGFR2.18 VEGF is an important angiogenic
mediator that acts specifically on vascular endothelial cells
to increase vascular permeability, and stimulates endo-
thelial cell proliferation, migration, and tube forma-
tion.10,13 VEGF pathway activation significantly accelerates
gastric ulcer healing by enhancing angiogenesis at the ulcer
site.19 The study showed that ulcer activated VEGF and
VEGFR2 expression to promote ulcer healing physiologi-
cally, but clopidogrel treatment significantly inhibited
ulcer-induced VEGF/VEGFR2-ERK expression over the ulcer
margin and then inhibited the angiogenesis of ulcer healing.
Our findings echo those of Ma et al,8 which showed that
ticlopidine, another ADP receptor antagonist, impaired
angiogenesis and gastric ulcer healing in rats with
decreasing VEGF level.8
In the in vitro part of this study, we demonstrated that
VEGF activated VEGFR especially VEGFR2, then upregulated
ERK/pERK signal transduction pathway, but not PI3K or P38
pathway and finally promoted HUVEC proliferation. These
findings were consistent with previous studies which
showed that VEGF induced HUVEC angiogenesis via stimu-
lating the Ras-MEK-ERK pathway, which was blocked by MEK
inhibitor PD9805920,21 and that VEGF bound the VEGF re-
ceptor and activated ERK1/2 through the phospholipase g
(PLC-g) PKC-a-B-Raf-pathway and then induced HUVEC
proliferation.22 We found that clopidogrel inhibited VEGF-
stimulated HUVEC proliferation by downregulation of
VEGFR2 and pERK. Angiogenesis is a multiple-step process
involving cell migration, proliferation of endothelial cells
and their subsequent realignment to form new capillary
tubes.23 In our in vitro study, only HUVEC proliferation via
MTT method was assayed. Further studies to evaluate the
action and mechanisms of clopidogrel on Matrigel invasion
assay and migration assay are needed in the future.
This study showed that clopidogrel inhibited the angio-
genesis of gastric ulcer healing and delayed rat gastric
ulcer healing via inhibiting VEGF-VEGFR2-ERK signal trans-
duction pathway. Our previous study showed that clopi-
dogrel delays gastric ulcer healing in rats via inhibiting
gastric epithelial cell proliferation, at least by inhibition of
the EGF receptor-ERK signal transduction pathway. Clopi-
dogrel delays gastric ulcer healing involving ERK signal
transduction pathway and inhibits gastric mucosal cell
proliferation and mucosa/submucosal angiogenesis. These
findings corroborate previous clinical study that clopidogrel
is not safe enough for the gastric mucosa of patients with a
history of aspirin-associated ulcer or ulcer bleeding when
they took clopidogrel after the ulcer had healed.1
Furthermore, ulcer recurred at previous ulcer locations
among these patients.4,24 It seems that ADP receptor an-
tagonists, both ticlopidine and clopidogrel, cause no gastric
mucosa injury,3,7 but they did delay gastric ulcer
healing.8,15,7
Figure 5 Effects of vascular endothelial growth factor (VEGF) with or without clopidogrel on messenger RNA expression of VEGF
receptors measured by real-time polymerase chain reaction. Values are mean  standard deviation. n Z 6 in each group. * In-
dicates p < 0.05 when compared with each other.
Clopidogrel inhibits ulcer healing 771In conclusion, clopidogrel inhibits the angiogenesis of
gastric ulcer margin and delays gastric ulcer healing, which
is associated with inhibiting VEGF-VEGFR2-ERK signal
transduction pathway.Acknowledgments
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